Showing results (61-70 of 115) with videos related to

Sort By:
Pageof 12
Blood Advances|August 8, 2025
NKTR-255 Enhances Complete Response Following CD19 CAR-T in Patients with Relapsed/Refractory Large B-cell LymphomaSairah Ahmed, John F DiPersio, James H Essell, et al.
Blood|May 8, 2012
Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidenceSally Arai, Bita Sahaf, Balasubramanian Narasimhan, et al.
Blood Advances|August 21, 2019
Nonmyeloablative TLI-ATG conditioning for allogeneic transplantation: mature follow-up from a large single-center cohortMichael A Spinner, Vanessa E Kennedy, John S Tamaresis, et al.
Blood Advances|January 4, 2018
HLA-mismatched unrelated donor transplantation using TLI-ATG conditioning has a low risk of GVHD and potent antitumor activityMichael A Spinner, Marcelo Fernández-Viña, Lisa E Creary, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 21, 2017
Anti-Platelet-Derived Growth Factor Receptor Alpha Chain Antibodies Predict for Response to Nilotinib in Steroid-Refractory or -Dependent Chronic Graft-Versus-Host DiseaseGeorge L Chen, Paul A Carpenter, Raewyn Broady, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 8, 2016
The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host DiseaseKenneth R Cooke, Leo Luznik, Stefanie Sarantopoulos, et al.
Transplantation and Cellular Therapy|August 26, 2024
Tocilizumab Prophylaxis Following Axicabtagene Ciloleucel in Relapsed or Refractory Large B-Cell LymphomaFrederick L Locke, Sattva S Neelapu, Nancy L Bartlett, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 31, 2006
Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker Working Group ReportKirk R Schultz, David B Miklos, Daniel Fowler, et al.
Transplantation and Cellular Therapy|November 14, 2025
CRS or ICANS Are Rare Beyond 2 Weeks After Lisocabtagene Maraleucel Infusion: Data From Clinical Trials and the Real-World SettingBradley D Hunter, Matthew Lunning, Mazyar Shadman, et al.
Blood Advances|September 3, 2021
Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphomaSattva S Neelapu, Frederick L Locke, Nancy L Bartlett, et al.
Pageof 12